亚盛于2025 ASCO 大会以口头报告形式展示了Lisaftoclax 联用在美国和澳洲人群包含AML MDS 在内的恶性髓系肿瘤数据,其中Venetoclax耐药R/R AML/MPAL 人群显示出的31.8% ORR 令人惊喜。我们认为,若后续能在更大样本量下Venetoclax 耐药R/R AML 人群持续显示不错的疗效数据,Lisaftoclax 有望打开R/R AML 在美国及海外的...
Source Link亚盛于2025 ASCO 大会以口头报告形式展示了Lisaftoclax 联用在美国和澳洲人群包含AML MDS 在内的恶性髓系肿瘤数据,其中Venetoclax耐药R/R AML/MPAL 人群显示出的31.8% ORR 令人惊喜。我们认为,若后续能在更大样本量下Venetoclax 耐药R/R AML 人群持续显示不错的疗效数据,Lisaftoclax 有望打开R/R AML 在美国及海外的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.